RespireRx Pharmaceuticals Inc.
RSPI
$0.0021
$0.0011110.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 245.10K | 367.60K | 291.90K | 191.70K | 250.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 332.50K | 465.90K | 390.40K | 221.00K | 389.00K |
| Operating Income | -332.50K | -465.90K | -390.40K | -221.00K | -389.00K |
| Income Before Tax | -395.50K | -681.00K | -430.10K | -289.70K | -472.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -395.50K | -681.00K | -430.10K | -289.70K | -472.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -395.50K | -681.00K | -430.10K | -289.70K | -472.60K |
| EBIT | -332.50K | -465.90K | -390.40K | -221.00K | -389.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 267.73M | 168.21M | 137.18M | 121.84M | 119.26M |
| Average Diluted Shares Outstanding | 267.73M | 168.21M | 137.18M | 121.84M | 119.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |